Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Effects of Angiotensin-(1-7) in Obesity and Insulin Resistance
NCT02646475Phase 1Recruiting
- Sponsor
- Vanderbilt University
- Start
- Feb 2016
- Primary completion
- Dec 2029
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of angiotensin-(1-7) in insulin resistance (IR), obesity, hypertension (HTN) and 1 more (2 arms), sponsored by Vanderbilt University. Primary endpoint: Whole-Body Insulin Sensitivity. Started Feb 2016; status: recruiting.
02
Drugs
angiotensin-(1-7)
03
Conditions
insulin resistance (IR)obesityhypertension (HTN)metabolic syndrome
Beyond the preview
Go deeper on NCT02646475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646475.